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ABSTRACT Nitric oxide (NO) produced by the endothe-
lium diffuses both into the lumen and to the smooth muscle
cells according to the concentration gradient in each direc-
tion. The extremely high reaction rate between NO and
hemoglobin (Hb), kHb5 3–5 3 107 M21zs21, suggests that most
of the NO produced would be consumed by Hb in the red blood
cells (RBCs), which then would block the biological effect of
NO. Therefore, specific mechanisms must exist under physi-
ological conditions to reduce the NO consumption by RBCs,
in which the Hb concentration is very high (24 mM heme). By
using isolated microvessels as a bioassay, here we show that
physiological concentrations of RBCs in the presence of
intravascular f low does not inhibit NO-mediated vessel dila-
tion, suggesting that RBCs under this condition are not an NO
scavenger. On the other hand, RBCs (50% hematocrit) without
intravascular f low reduce NO-mediated dilation to serotonin
by 30%. In contrast, free Hb (10 mM) completely inhibits
NO-mediated dilation with or without intravascular f low. The
effect of f low on NO consumption by RBCs may be attributed
to the formation of an RBC-free zone near the vessel wall,
which is caused by hydrodynamic forces on particles. Intra-
vascular f low does not affect the reaction rate between NO and
free Hb in the lumen, because the latter forms a homogeneous
solution and is not subject to the hydrodynamic separation.
However, intravascular f low only partially contributes to the
reduced consumption of NO by RBCs, because without the
f low, the NO consumption by RBCs is already about 3 orders
of magnitude slower than free Hb.
Nitric oxide (NO) is a biological messenger that participates in
neurotransmission, vascular regulation, and immunological
responses. It is produced in many cell types such as neurons,
endothelial cells vascular smooth muscle cells, and macro-
phages. Since the discovery of its biological activity, the roles
of NO in physiological and pathophysiological processes have
been seen as increasingly important. In the cardiovascular
system, NO has been documented to participate in the regu-
lation of vascular tone and permeability (1, 2), platelet adhe-
sion and aggregation (3, 4), smooth muscle proliferation (5, 6),
and endothelial cell-leukocyte interactions (1, 7). The func-
tions of NO in vivo have been clearly demonstrated by admin-
istration of L-arginine analogs that block NO production. For
example, the administration of NG-monomethyl-L-arginine
(L-NMMA) has been shown to cause hypertension in vivo (8)
and abolish shear-induced, NO-mediated vessel dilation both
in vivo (9) and in isolated intact vessel preparation (10).
Despite the well-documented importance of NO, the trans-
fer of NO from the producing cell to the target is poorly
understood, because NO, as a free radical, can be degraded in
a variety of reactions. In particular, NO reacts with deoxy- and
oxy-hemoglobin (Hb) at a very high rate to form nitrosyl-Hb
(HbNO), and metHb, respectively. The bimolecular reaction
rate constants for these reactions are on the order of 3–5 3 107
M21zs21 (11, 12), which gives a half-life of about 1 msec for NO
in blood according to the direct interpretation of the in vitro
data. With this short half-life, the concentration of NO would
be too low to activate its target enzyme, soluble guanylate
cyclase. Indeed, modeling analyses have shown that if oxyHb
in the red blood cell (RBC) reacts with NO as fast as free Hb
does, then the NO concentrations in vascular smooth muscle
will be too low to activate soluble guanylate cyclase (13, 14),
the main target enzyme for NO.
Several lines of in vivo and in vitro evidence suggest that Hb
is an effective NO scavenger that depletes NO. For example,
infusion of a free Hb solution into experimental animals or
human subjects results in hypertension (15), most likely be-
cause of the oxidative reaction of NO with oxyHb in the
circulation. Furthermore, 3–6 mM of free Hb can abolish
NO-mediated vasodilation in vitro (16, 17). Given these results,
it is unclear how NO exerts any regulatory function in vivo,
where the normal Hb concentration in the blood is about 12–15
mM (heme basis), almost 1,000 times higher than that required
for free Hb to abolish the NO effect.
Several theories have been proposed to explain this paradox.
In particular, the formation of S-nitrosyl Hb (18, 19) has been
suggested as a mechanism to package and transport NO.
Independent of this theory, external diffusion limitation has
been implicated in reducing the rate of NO consumption by
RBCs (14, 20, 21). The external limitation may be caused by
either an undisturbed (boundary) layer surrounding each RBC
(20) or an RBC-free zone near the vessel wall (14, 21). Liu et
al. (20) have shown that the NO consumption by a dilute RBC
suspension is much slower than that of a free Hb solution with
an equivalent Hb concentration. This observation was attrib-
uted to the undisturbed layer surrounding each RBC. Vaughn
et al. (14) used a diffusion and reaction model to predict that
the existence of an RBC-free zone would increase the NO
concentration in the smooth muscle layer by 2- to 3-fold.
Whether such an increase is physiologically significant remains
to be determined. Butler et al. (21) also modeled the NO
diffusion and reaction system in a vessel with an RBC-free
zone. Under their assumptions, the model shows that the
existence of the RBC-free zone allows the outflow of NO into
the smooth muscle layer. Therefore, intravascular flow may
affect the NO consumption rate by RBCs. Intuitively, it can be
argued that intravascular flow would reduce the thickness of
the undisturbed layer and thus increase NO consumption by
RBC. On the other hand, intravascular flow also generates an
RBC-free zone near the vessel wall and thus reduces the
interaction between the endothelial released NO and RBC.
Therefore, the net effect of flow on NO consumption by RBCs
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is difficult to predict. By using isolated microvessels as a
bioassay, we investigated the effect of intravascular flow on
NO consumption by RBCs under physiological levels of he-
matocrit.
MATERIALS AND METHODS
General Preparation. Pigs (12 weeks old of either sex) were
sedated with intramuscular injection of telazol (4.4 mgykg) and
xylazine (2.2 mgykg), then anesthetized and heparinized with
an i.v. injection with pentobarbital sodium (20 mgykg) and
heparin (1,000 unitsykg), respectively, via the marginal ear
vein. Pigs were intubated and ventilated with room air. After
a left thoracotomy was performed, the heart was electrically
fibrillated, excised, and immediately placed in cold (5°C) saline
solution, and the blood was collected for RBC isolation.
Isolation and Cannulation of Microvessels. The techniques
for identification and isolation of coronary microvessels have
been described (22, 23). In brief, a mixture of India ink and
gelatin in physiological salt solution (PSS) containing 145.0
mM NaCl, 4.7 mM KCl, 2.0 mM CaCl2, 1.17 mM MgSO4, 1.2
mM NaH2PO4, 5.0 mM glucose, 2.0 mM pyruvate, 0.02 mM
EDTA, and 3.0 mM 3-(N-morpholino) propanesulfonic acid
(Mops) buffer was perfused under a low pressure (20 cm H2O)
into the left anterior descending artery (0.5 ml) and the
circumflex artery (0.5 ml) to enable visualization of the
coronary microvessels. Subepicardial arteriolar branches (50–
100 mm internal diameter and 0.6–1.0 mm in length without
branches) from the left anterior descending or circumflex
arteries were selected and carefully dissected from the sur-
rounding cardiac tissue under cold (5°C) PSS containing 1%
of BSA (Amersham Pharmacia) at pH 7.4. Each isolated
arteriole then was transferred for cannulation to a Lucite vessel
chamber containing PSS-albumin equilibrated with room air at
ambient temperature. One end of the microvessel was cannu-
lated with a glass micropipette (40 mm in tip diameter) filled
with filtered PSS-albumin, and the outside of the microvessel
was securely tied to the pipette with 11-O ophthalmic suture
(Alcon Laboratories, Fort Worth, TX). The ink-gelatin solu-
tion inside the vessel was flushed out at a low perfusion
pressure (,20 cm H2O). Then, the other end of the vessel was
cannulated with a second micropipette and tied with suture.
We previously have shown that the ink-gelatin solution has no
detectable detrimental effect on either endothelial or vascular
smooth muscle function. (22, 23). Electrical resistances (mea-
sured by LCR Bridge Circuit, model LCR-740, Leader Elec-
tronics, Yokohama, Japan) of the micropipettes were matched
(6 0.5%).
Instrumentation. After cannulation of a blood vessel, the
chamber was transferred to the stage of an inverted micro-
scope (model IM35, Zeiss) coupled to a charge-coupled device
camera (KP-161, Hitachi), video micrometer (Microcircula-
tion Research Institute, Texas A&M University Health Sci-
ence Center), and video recorder (JVC BR-S600U). The
micropipettes were connected to independent reservoir sys-
tems, and intravascular pressures were measured through
sidearms of the two reservoir lines by low-volume displace-
ment strain-gauge transducers (Statham P23 Db, Gould,
Cleveland). The vessel was set to its in situ length and allowed
to develop a spontaneous tone at 60 cm H2O luminal pressure
without flow. This pressure corresponds to that found in
arterioles of similar sizes in the beating heart (24). After the
vessel developed basal tone, the experimental interventions
were performed and internal diameters of the vessel were
measured throughout the experiment by using video micro-
scope with a data acquisition system (25).
RBC Isolation and OxyHb Preparation. The RBCs were
isolated by the method of Beutler (26). Briefly, a column was
prepared by pouring a 1:1 (dry weight) mixture of a-cellulose
and microcrystalline cellulose (Sigmacell type 50, Sigma)
mixed with PSS into the barrel of a 10-ml syringe. The syringe
was filled to the 4-ml mark and washed with 5 ml of PSS. Two
milliliters of blood was allowed to flow through the column and
washed through with PSS. The cell suspensions from several
columns were diluted about 103 by ice-cold PSS and centri-
fuged at 850 g for 15 min. This washing procedure was repeated
once. The packed erythrocytes were suspended in 13 volume
of PSS. Before use, the erythrocytes were washed again to
remove any free Hb caused by possible lysis. During the
purification and washing processes, the RBC was almost
completely oxygenated, as confirmed spectrophotometrically.
Porcine Hb was prepared from lyophilized powder (Sigma)
by the method of Di Iorio (27). Briefly, Hb was dissolved in
PSS to prepare a stock solution of approximately 1 mM. To
assure that the Hb was in the ferrous form, the Hb solution was
cooled to 4°C, reduced with sodium dithionite, and immedi-
ately desalted by passing through a column of Sephadex G-25
(Amersham Pharmacia) that had been previously equilibrated
with 4°C PSS. The concentration of the resulting Hb was
assayed by spectrophotometer. The Hb was refrigerated and
used within 2 days. Before the experiment, the Hb was
oxygenated with 95% O2 for 5 min.
Effect of Hb and RBCs on NO-Mediated Coronary Arte-
riolar Dilation. We previously have demonstrated that coro-
nary arteriolar dilation in response to flow (shear) (25) and
serotonin (28) stimulation is mediated by the NO released
from the endothelium. To study the effect of Hb and RBCs on
NO-mediated flow-induced vasodilation, the vascular re-
sponse to a vehicle flow driven by a pressure gradient (DP 5
4, 10, 20, 40, and 60 cm H2O) across the length of the vessel
initially was examined. The luminal f low was produced by
simultaneously moving the reservoirs in opposite directions of
the same magnitude. We have demonstrated that the luminal
f low is increased linearly with increasing DP and the range of
mean volumetric f lows for DP between 0 and 60 cm H2O was
0–34.8 nlysec. The effect of Hb or RBCs on flow-induced
vasodilation was examined by perfusing the vessels with PSS
containing various concentrations of Hb or RBCs. To study the
effect of Hb and RBCs on serotonin-induced dilation, the
vessels were pressurized without flow by setting both reservoirs
to the same hydrostatic level. Serotonin (10210 M to 1026 M)
was administered cumulatively into the vessel bath, and the
concentration-dependent dilation was examined in the ab-
sence (vehicle control) and presence of luminal RBCs or Hb.
Chemicals and drugs were obtained from Sigma, except when
stated otherwise.
Data Analysis. At the end of each experiment, the vessel was
relaxed with sodium nitroprusside (1024 M) to obtain its
maximal diameter at 60 cm H2O intraluminal pressure (28). All
diameter changes were normalized to the maximal diameter
and expressed as a percentage of maximal dilation. All data are
presented as mean 6 SEM. Statistical comparisons of dose- or
flow-dependent vasomotor responses under various treat-
ments were performed with one- or two-way ANOVA when
appropriate and tested with Fisher’s protected least significant
difference multiple range test. Differences in resting diameter
in response to serotonin (1027 M) before and after Hb or RBC
treatments were compared by the paired Student’s t test.
Significance was accepted at P , 0.05.
RESULTS
Intravascular Flow Does Not Affect the NO Consumption
Rate by Free Hb. To establish the effect of free Hb on
NO-mediated dilation in the absence of flow, the vessel was
dilated by serotonin, which has been shown to induce NO-
mediated dilation in coronary microvessels (28). After pres-
surizing the vessel to 60 cm H2O luminal pressure without flow
by setting both reservoirs to the same hydrostatic level, sero-
tonin (10210 M to 1026 M) was administered cumulatively into
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the vessel bath, and the concentration-dependent dilation was
examined in the absence (vehicle control) and presence of
luminal Hb. Results show that free Hb (10 mM) significantly
reduced serotonin-induced dilation at doses ranging from
10210 to 1027 M (Fig. 1). The effect of free Hb is identical to
that of the NO synthase inhibitor, L-NMMA (10 mM), sug-
gesting that the inhibitory effect of free Hb can be attributed
to the reduction of NO concentration. These results show that
free Hb, indeed, is a potent NO scavenger and functionally
inhibits NO-mediated dilation of pressurized microvessels,
even at a concentration as low as 10 mM.
To investigate the effect of flow on NO interaction with free
Hb, the vascular response to flow (DP 5 4, 10, 20, 40, and 60
cm H2O) in the absence and presence of luminal Hb was
examined. In the absence of luminal Hb, increasing intravas-
cular flow resulted in dilation of coronary arterioles (Fig. 2).
However, this f low-induced dilation was significantly inhibited
by 1 mM Hb (expressed in heme concentration) and was
abolished by 10 mM Hb. Comparing the effects of free Hb (10
mM) on serotonin-induced and flow-induced dilation, we
found that the presence of flow does not affect NO consump-
tion by free Hb. In both cases, 10 mM of free Hb eliminated
the NO-mediated dilation, identical to the effect of L-NMMA
(Fig. 2).
Intravascular Flow Reduces the NO Consumption by RBCs.
To investigate the effect of flow on NO consumption by RBCs,
we examined the influence of RBCs on NO-mediated dilation
in the absence and presence of intravascular flow. In the
FIG. 1. NO mediated vasodilation to serotonin was attenuated by
10 mM oxyHb, giving a response identical to that of NOS inhibitor
L-NMMA (10 mM). Basal diameter 5 76 6 2 mm, maximum diame-
ter 5 98 6 3 mm; P , 0.05 versus control.
FIG. 2. Flow-induced vasodilation was attenuated by oxyHb in a
dose-dependent manner. Vasodilatory response to the increased flow
was completely abolished by 10 mM oxyHb, identical to that of NOS
inhibitor L-NMMA (10 mM). n 5 5, basal diameter 5 74 6 4 mm;
maximum diameter 5 112 6 3 mm; p, P , 0.05, all interventions versus
control.
FIG. 3. The vasodilation in response to serotonin (0.1 mM) was
significantly inhibited by free oxyHb and RBCs with 50% or 90%
hematocrit (corresponding to 3 and 5.6 mM overall Hb, respectively).
Fifty percent hematocrit (3.1 mM Hb) had less inhibition to serotonin-
induced dilation than 10 mM free oxyHb. n 5 5, basal diameter 5 76 6
2 mm, maximum diameter 5 98 6 3 mm; p, P , 0.05, versus control;
1, P , 0.05, versus 50% hematocrit.
FIG. 4. The vasodilatory response to the increased flow (i.e.,
pressure gradient) during perfusion with a PSS or RBCs. The flow-
induced vasodilation, especially at the lower flow rates, was slightly
inhibited by RBCs. n 5 5, basal diameter 5 78 6 4 mm, maximum
diameter 5 104 6 3 mm.
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absence of flow, serotonin was used to induce NO production
in a vessel containing an RBC suspension in the lumen.
Interestingly, the luminal solution containing 50% hematocrit
(about 12 mM of overall heme) reduced serotonin-induced
dilation by 30% (Fig. 3), much less than the effect of 10 mM
of free Hb. To inhibit serotonin-induced dilation to the same
extent as free Hb (10 mM), a 90% hematocrit, i.e., about 21
mM of heme, was required (Fig. 3). These results suggest that
NO consumption by RBCs is slower than that of free Hb by at
least 3 orders of magnitude.
To investigate the effect of RBCs in the presence of intra-
vascular flow, vessel dilation was induced by flow with and
without RBC suspension in the perfusion solution. If f low had
no effect on the RBC-NO interaction, one would expect that
an RBC suspension at about 50% hematocrit should reduce
dilation by about 30%, similar to the RBC effect on serotonin-
induced dilation. Unexpectedly, when the vessel was perfused
with RBCs at 60% hematocrit (corresponding to 14 mM of
overall heme concentration), f low-induced vasodilation was
not affected (Fig. 4). This result suggests that intravascular
flow decreased NO consumption by RBCs. Fig. 5 summarizes
the effects of intravascular flow on inhibition of NO-mediated
dilation by free Hb and RBCs. It shows that free Hb (10 mM)
effectively inhibited NO-mediated dilation in response to
either serotonin (1027 M) or shear stress (DP 5 60 cm H2O).
The presence of flow does not attenuate the effect of free Hb.
In contrast, NO-mediated vessel dilation was hardly affected
by flowing RBCs (50–60% hematocrit).
DISCUSSION
The above results demonstrate two important findings. First,
NO consumption by RBCs is slower than free Hb by about 3
orders of magnitude. Second, intravascular flow further re-
duces the NO consumption by RBCs. In contrast, intravascular
flow does not affect NO consumption by free Hb. The low NO
consumption rate by RBCs is consistent with our prediction
based on mathematical modeling (14). However, the effect of
flow on NO consumption by RBCs is not readily predicted. As
described above, intravascular flow may generate two possible
effects on NO consumption. The first is the reduction of
diffusion distance through more efficient micro mixing. This
effect tends to increase the NO consumption by RBCs, inhib-
iting the vessel dilation. The second is the creation of an
RBC-free zone, which reduces the NO consumption by RBCs.
The latter effect appears dominant, and thus intravascular flow
reduces the scavenging effect of RBC and allows the released
NO to exert its vasodilatory function. This RBC-free zone
varies with shear stress and can be as much as 20–25% of the
lumen diameter in thickness (29). In contrast, free Hb exists as
a homogeneous solution with or without flow. Therefore, f low
has no effect on NO consumption by free Hb. In addition to
the induction and activation of NO synthase by shear stress,
intravascular flow reduces NO consumption by RBC and thus
generally enhances NO availability for its biological action.
The above results suggest that the RBC-free zone near the
vessel wall is important in reducing the NO consumption by
RBCs. However, the RBC-free zone does not completely
explain the low NO consumption rate by RBCs. Even without
this phenomenon (e.g., in serotonin-induced dilation), the NO
consumption by RBC is still much lower than free Hb (Fig. 3).
This difference also has been observed previously under
conditions without the RBC-free zone (20, 30–32).
Fig. 4 demonstrates that under physiological conditions
(40–50% hematocrit and in the presence of flow), RBC
suspension is not an NO scavenger. Previously, several theories
have been proposed to explain why NO is not scavenged by
RBCs. Notably, S-nitrosylation of Hb to form Cysb93-nitrosyl
Hb (SNO-Hb) has been proposed to be a mechanism bypassing
the NO scavenging problem (19). In this mechanism, Hb was
suggested to be an NO carrier rather than an NO scavenger.
Gow and Stamler (19) proposed a dynamic sequence as part of
blood pressure control. According to this theory, in the veins
(deoxy conditions), Hb (T state) binds to NO at the heme site.
Upon oxygenation (T to R transition), bFe(II)NO can transfer
NO to the b93Cys group to form SNO-Hb (R state). When
SNO-Hb circulates to the arterioles and capillaries (deoxy), the
SNO group is released to dilate the vessels, and, at the same
time, NO produced from local endothelium is bound to the
heme group to complete the cycle. Although the SNO-Hb
theory is innovative and interesting, it does not address the
issue of NO scavenging by Hb. It is recognized and experi-
mentally shown (unpublished results) that S-nitrosylation does
not reduce the rate of NO reaction with the oxygen bound to
the heme group. Moreover, the rate of the S-nitrosylation
reaction is much slower than that of the NO-oxyHb reaction,
and thus the majority of NO will be oxidized by oxyHb. Indeed,
the SNO-Hb measured in rats (18) was at most in the 400 nM
range, 4 orders of magnitude lower than the total Hb in blood
(about 12 mM of heme). Therefore, regardless of the physio-
logical role of SNO-Hb, this proposed mechanism alone
cannot explain why NO is not degraded by Hb in blood. The
success of the SNO-Hb theory thus requires a mechanism to
prevent NO from being completely scavenged. The results
reported here, along with the undisturbed layer theory (20),
may partially provide such missing mechanisms.
Why the RBC does not scavenge NO, even without the
RBC-free zone, is still incompletely understood. Liu et al. (20)
suggested that the undisturbed layer surrounding RBCs cre-
ated sufficient diffusion resistance. Yonetani et al. (33) suggest
that low concentrations of NO in blood (1027 to 1025 M) under
partial oxygenation is scavenged by deoxyHb, rather than by
oxyHb, to form a(Fe-NO)2b(Fe)2, (kon 5 107 M21zs21). This
product is a cooperative, low affinity oxygen carrier that can
deliver oxygen to tissue. The a(Fe-NO)2b(Fe)2 eventually is
oxidized to nitrate and met-hemes by oxygen with a half-life of
about 30 min. This observation may nicely explain the fate of
NO under low oxygenation conditions, but does not address
the NO scavenging issue. The binding of NO to a-hemes occurs
almost as fast as the reaction of NO with oxyHb, and NO
FIG. 5. Summary of the effect of flow on inhibition of vasodilation
by free Hb and RBCs from Figs. 1–4. The presence of flow reduced
the inhibitory effect of RBCs (50–60% hematocrit) on NO-mediated
vessel dilation [1, P , 0.05, serotonin (5-HT) versus flow, DP 5 60 cm
H2O]. In contrast, f low did not change the effect of free Hb. Free Hb
(10 mM) effectively inhibited NO-mediated dilation in response to
either serotonin (0.1 mM) or shear stress (DP 5 60 cm H2O), but RBCs
(50–60% hematocrit) had significantly less effect. p, P , 0.05, RBCs
versus free Hb.
8760 Physiology: Liao et al. Proc. Natl. Acad. Sci. USA 96 (1999)
eventually is oxidized. Therefore, this theory requires some
other mechanisms to reduce the NO uptake rate by RBCs. The
extracellular diffusion layer proposed by Liu et al. (20) pro-
vides a possible explanation. Here we show that the RBC-free
zone is partially responsible for the reduction of NO consump-
tion rate by RBCs. This finding is important because the
RBC-free zone is increasingly significant in the microcircula-
tion where blood flow is actually controlled. The reduced NO
consumption by RBCs in the microcirculation might enhance
the effective NO diffusion distance (14) for vasoregulation.
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